- Partnering with Amneal to commercialize recent USFDA approved product
- Represents another new product launch for Strides in 2023
Strides Pharma Science Limited and Amneal Pharmaceuticals, Inc. Amneal have jointly announced the introduction of Icosapent ethyl acid soft gel capsules, referencing VASCEPA®. This pharmaceutical product, licensed from Strides, a global pharmaceutical manufacturer, is set to be launched by Amneal in the fourth quarter of 2023.
Icosapent ethyl acid soft gel capsules in 0.5g and 1g formulations consist of an ethyl ester of eicosapentaenoic acid (EPA). These capsules are indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
Strides Pharma and Amneal Pharmaceuticals Details
Aditya Kumar, Vice President Business Development at Strides Pharma Science Limited, expressed enthusiasm about the partnership, stating, “We are thrilled to announce our partnership with Amneal Pharmaceuticals for Icosapent ethyl acid soft gelatin capsules. This partnership is a testament to our commitment to excellence and the pursuit of cutting-edge solutions. By combining our resources, expertise, and shared passion, we are confident that we will achieve remarkable outcomes that benefit not only our organizations but also our valued customers and stakeholders.”
Andy Boyer, Executive Vice President, Amneal Generics, highlighted the company’s ambitious plans, stating, “We are on-track to launch over 40 new products in 2023. The launch of Icosapent ethyl is another essential medicine that we’ve added to our portfolio.”
The Important Safety Information for VASCEPA® includes adverse effects such as musculoskeletal pain, peripheral edema, constipation, gout, and atrial fibrillation. For complete prescribing information, please refer to the package insert available